Astal signs LoI with Immuna Therapeutics

Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation

Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies

Harbour BioMed brings advanced antibody discovery platforms to the table

Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe

Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor

Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China

Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data

Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option

Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027

Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug

The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa

Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar

Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized